| Literature DB >> 32751810 |
Daria Schneider-Matyka1, Małgorzata Szkup1, Aleksander Jerzy Owczarek2, Marzanna Stanisławska1, Anna Knyszyńska3, Anna Lubkowska3, Elżbieta Grochans1, Anna Jurczak4.
Abstract
Background andEntities:
Keywords: IFNG polymorphism; chronic inflammation; metabolic syndrome; women’s health
Mesh:
Substances:
Year: 2020 PMID: 32751810 PMCID: PMC7466241 DOI: 10.3390/medicina56080384
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Characteristics of the study sample with regard to a division into MetS+ and MetS− groups.
| MetS+ | MetS− |
| |
|---|---|---|---|
|
| |||
| waist size (cm) | 93.3 ± 11.0 | 85.4 ± 11.2 |
|
| MetS symptom definition—waist size (cm); N (%) | 97 (82.2) | 62 (20.8) |
|
| fasting glycemia (mg/dL) | 100.8 (86.9–119.0) | 83.2 (77.4–90.7) |
|
| MetS symptom definition—hyperglycemia; N (%) | 60 (50.8) | 14 (4.7) |
|
| TG (mg/dL) | 137.6 (102.0–189.8) | 84.8 (65.0–112.1) |
|
| MetS symptom definition—TG; N (%) | 75 (63.6) | 32 (10.7) |
|
| HDL (mg/dL) | 56.5 ± 16.8 | 70.0 ± 16.0 |
|
| MetS symptom definition—HDL; N (%) | 61 (51.7) | 21 (7.1) |
|
| systolic blood pressure (mmHg) | 137.2 ± 15.3 | 119.1 ± 14.8 |
|
| diastolic blood pressure (mmHg) | 83.9 ± 9.4 | 75.9 ± 9.7 |
|
| Mets symptom definition—hypertension; N (%) | 97 (82.2) | 62 (20.8) |
|
|
| |||
| IL-1α (pg/mL) | 1.85 (1.46–2.42) | 2.09 (1.50–2.59) | 0.079 |
| IL-1β (pg/mL) | 13.64 (5.60–102.00) | 12.39 (3.41–218.30) | 0.801 |
| IL-6 (pg/mL) | 11.23 (5.51–34.47) | 8.21 (3.65–21.46) |
|
| TNFα (pg/mL) | 4.06 (2.00–6.85) | 0.05 (0.03–0.14) | 0.495 |
| IFNγ (IU/mL) | 0.04 (0.03–0.21) | 1.90 (1.30–3.20) | 0.936 |
mean ± standard deviation; median (lower quartile–upper quartile); p—significance level. PICs—proinflammatory cytokines; CRP—C-reactive protein; IL—interleukin; TNFα—tumor necrosis factor α; IFNγ—interferon γ; MetS—Metabolic syndrome; TG—elevated serum triglyceride; HDL—high-density lipoprotein. Bold words shows that results are statistically significant.
Analysis of the relationship between the IFNG (rs2430561) polymorphism and the levels of IL-1α, IL-1β, IL-6, TNFα and IFNγ with regard to MetS.
|
| MetS+ | MetS− | ||
|---|---|---|---|---|
| Mean Value (SE); | Mean Value (SE); | Δ | ±95% CI | |
| log10 (IL-1α (pg/mL)) | ||||
| T/T | 0.311 (0.045); 56 | 0.397 (0.040); 132 | −0.085 | −0.210 ÷ 0.040 |
| A/T | 0.283 (0.027); 41 | 0.362 (0.033); 120 | −0.079 | −0.221 ÷ 0.063 |
| A/A | 0.385 (0.127); 21 | 0.369 (0.064); 46 | 0.016 | −0.191 ÷ 0.222 |
| log10 (IL-1β (pg/mL)) | ||||
| T/T | 1.209 (0.129); 47 | 1.242 (0.097); 107 | −0.034 | −0.387 ÷ 0.319 |
| A/T | 1.350 (0.155); 33 | 1.366 (0.110); 100 | −0.016 | −0.421 ÷ 0.389 |
| A/A | 1.593 (0.220); 20 | 1.408 (0.203); 20 | 0.185 | −0.378 ÷ 0.748 |
| log10 (IL-6 (pg/mL)) | ||||
| T/T |
|
|
| |
| A/T |
|
|
| |
| A/A | 0.915 (0.146); 2 | 0.893 (0.072); 42 | 0.021 | −0.332 ÷ 0.375 |
| log10 (TNFα (pg/mL)) | ||||
| T/T | 0.641 (0.079); 43 | 0.553 (0.047); 107 | 0.087 | −0.078 ÷ 0.253 |
| A/T | 0.561 (0.072); 31 | 0.535(0.044); 105 | 0.026 | −0.162 ÷ 0.213 |
| A/A | 0.599 (0.115); 17 | 0.518 (0.067); 41 | 0.081 | −0.184 ÷ 0.346 |
| log10 (INFγ (IU/mL)) | ||||
| T/T | −1.048 (0.156); 23 | −1.187 (0.054); 71 | −0.138 | −0.123 ÷ 0.400 |
| A/T | −0.951 (0.169); 20 | −1.077 (0.062); 67 | 0.126 | −0.152 ÷ 0.404 |
| A/A | −1.245 (0.126); 9 | −1.040 (0.115); 27 | −0.205 | −0.625 ÷ 0.214 |
N—number of cases; SE—standard error of the mean; ∆—mean difference between groups; ±95% CI—95% confidence interval, IL—interleukin, TNFα—tumor necrosis factor α, IFNγ—interferon γ. *—statistically significant based on the ±95% CI. Bold words shows that results are statistically significant。